MCID: FST001
MIFTS: 40

Foster-Kennedy Syndrome

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Foster-Kennedy Syndrome

MalaCards integrated aliases for Foster-Kennedy Syndrome:

Name: Foster-Kennedy Syndrome 12 15 17 72
Disorder of the Optic Nerve 72
Optic Nerve Diseases 44

Classifications:



External Ids:

Disease Ontology 12 DOID:14555
ICD9CM 35 377.04
MeSH 44 D009901
SNOMED-CT 68 87764000
ICD10 33 H47.14
UMLS 72 C0029132 C0152112

Summaries for Foster-Kennedy Syndrome

MalaCards based summary : Foster-Kennedy Syndrome, also known as disorder of the optic nerve, is related to chiasmal syndrome and meningioma, radiation-induced, and has symptoms including sciatica and eye manifestations. An important gene associated with Foster-Kennedy Syndrome is SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2), and among its related pathways/superpathways are Carbon metabolism and Pyruvate metabolism and Citric Acid (TCA) cycle. The drugs Bevacizumab and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include eye, bone and testes.

Wikipedia : 75 Foster Kennedy syndrome is a constellation of findings associated with tumors of the frontal... more...

Related Diseases for Foster-Kennedy Syndrome

Diseases related to Foster-Kennedy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Related Disease Score Top Affiliating Genes
1 chiasmal syndrome 11.1
2 meningioma, radiation-induced 10.8
3 meningioma, familial 10.8
4 spinal meningioma 10.8
5 secretory meningioma 10.8
6 lymphoplasmacyte-rich meningioma 10.8
7 3-methylglutaconic aciduria, type iii 10.7
8 papilledema 10.6
9 optic nerve disease 10.6
10 nonarteritic anterior ischemic optic neuropathy 10.5
11 spinal arachnoiditis 10.5
12 arachnoiditis 10.5
13 olfactory groove meningioma 10.5
14 posttransplant acute limbic encephalitis 10.5
15 neuropathy 10.4
16 intracranial hypertension 10.4
17 arteritic anterior ischemic optic neuropathy 10.3
18 optic neuritis 10.3
19 neuritis 10.3
20 cataract 10.3
21 juvenile nasopharyngeal angiofibroma 10.3
22 retinal disease 10.2
23 autoimmune disease 10.2
24 optic nerve hypoplasia, bilateral 10.2
25 spondylosis, cervical 10.2
26 temporal arteritis 10.2
27 hydrocephalus due to congenital stenosis of aqueduct of sylvius 10.2
28 retinitis pigmentosa 10.2
29 nasopharyngeal carcinoma 10.2
30 hydrops, lactic acidosis, and sideroblastic anemia 10.2
31 vitamin b12 deficiency 10.2
32 neuroretinitis 10.2
33 malignant hypertension 10.2
34 hydrocephalus 10.2
35 hemiplegia 10.2
36 arteriovenous malformation 10.2
37 telangiectasis 10.2
38 echinococcosis 10.2
39 retinal vein occlusion 10.2
40 spondylosis 10.2
41 malignant glioma 10.2
42 demyelinating disease 10.2
43 mammary paget's disease 10.2
44 retinitis 10.2
45 plasmacytoma 10.2
46 pituitary adenoma 10.2
47 peripheral nervous system disease 10.2
48 adenoma 10.2
49 neuromyelitis optica 10.2
50 scotoma 10.2

Graphical network of the top 20 diseases related to Foster-Kennedy Syndrome:



Diseases related to Foster-Kennedy Syndrome

Symptoms & Phenotypes for Foster-Kennedy Syndrome

UMLS symptoms related to Foster-Kennedy Syndrome:


sciatica, eye manifestations

Drugs & Therapeutics for Foster-Kennedy Syndrome

Drugs for Foster-Kennedy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
3
Levodopa Approved Phase 4 59-92-7 6047
4
Carbidopa Approved Phase 4 28860-95-9 34359
5
4-Aminopyridine Approved Phase 4 504-24-5 1727
6
Idebenone Approved, Investigational Phase 4 58186-27-9
7
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
8
Choline Approved, Nutraceutical Phase 4 62-49-7 305
9 Nootropic Agents Phase 4
10 Cytidine Diphosphate Choline Phase 4
11 Immunologic Factors Phase 4
12 Angiogenesis Inhibitors Phase 4
13 Angiogenesis Modulating Agents Phase 4
14 Antineoplastic Agents, Immunological Phase 4
15 Dopamine Agents Phase 4
16 Antiparkinson Agents Phase 4
17 Adjuvants, Immunologic Phase 4
18 Dopamine agonists Phase 4
19 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
20 Carbidopa, levodopa drug combination Phase 4
21 Potassium Channel Blockers Phase 4
22 Antioxidants Phase 4
23 Protective Agents Phase 4
24 Phosphodiesterase Inhibitors Phase 4
25 Phosphodiesterase 5 Inhibitors Phase 4
26 Sildenafil Citrate Phase 4 171599-83-0
27 Vardenafil Dihydrochloride Phase 4
28
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
29
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
30
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
31 Immunosuppressive Agents Phase 3
32 Analgesics Phase 3
33 Analgesics, Non-Narcotic Phase 3
34 Peripheral Nervous System Agents Phase 3
35 Anti-Inflammatory Agents, Non-Steroidal Phase 3
36 Anti-Inflammatory Agents Phase 3
37 Antirheumatic Agents Phase 3
38 Butylated Hydroxytoluene Phase 3
39 Mastic Phase 3
40 Endothelin Receptor Antagonists Phase 3
41 Pharmaceutical Solutions Phase 3
42 Hematinics Phase 3
43 Epoetin alfa Phase 3 113427-24-0
44 Central Nervous System Depressants Phase 3
45 Anesthetics Phase 3
46 Anti-Bacterial Agents Phase 3
47 Antibiotics, Antitubercular Phase 3
48 Anti-Infective Agents Phase 3
49
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
50
Alprostadil Approved, Investigational Phase 2 745-65-3 5280723 149351

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Cytidine-5’-diphosphocholine (Citicoline)
2 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
3 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
4 Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial Completed NCT01166594 Phase 4 Bevacizumab;Control
5 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
6 External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) Active, not recruiting NCT02774005 Phase 4 Idebenone
7 Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT00867815 Phase 4 Diagnostic procedures
8 Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02329288 Phase 3 Triamcinolone Acetonide;placebo
9 The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial Unknown status NCT02439866 Phase 3 placebo;Intravenous methylprednisolone;normobaric oxygen with face mask
10 Paraorbital-occipital Alternating Electric Current Stimulation in Patients With Optic Neuropathy Completed NCT01282827 Phase 2, Phase 3
11 A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON) Completed NCT00528151 Phase 3 curcumin
12 Ischemic Optic Neuropathy Decompression Trial (IONDT) Completed NCT00000127 Phase 3
13 A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION Recruiting NCT03547206 Phase 3 RPh201
14 Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT Recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
15 Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy Recruiting NCT02377271 Phase 3 bosentan;placebo
16 Erythropoietin in Methanol Associated Optic Neuropathy Active, not recruiting NCT02376881 Phase 3 Erythropoietin
17 Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year Active, not recruiting NCT03293524 Phase 3 Placebo
18 Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy Active, not recruiting NCT03153293 Phase 2, Phase 3 rAAV2-ND4
19 Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater Terminated NCT00359632 Phase 3 Zyvox - linezolid;Matched control
20 A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT02341560 Phase 2, Phase 3 QPI-1007 Injection - 1.5 mg;QPI-1007 Injection - 3.0 mg
21 Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) Withdrawn NCT01495715 Phase 3 Idebenone;Placebo
22 Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01834079 Phase 1, Phase 2
23 Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy Unknown status NCT02176733 Phase 2 cyclosporine
24 Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT01330524 Phase 1, Phase 2 Avastin and Triamcinolone
25 Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy Unknown status NCT00813059 Phase 2 Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
26 A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy Completed NCT00747487 Phase 2 Idebenone;Placebo
27 A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). Completed NCT02045212 Phase 2 RPh201;Placebo
28 Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy Completed NCT00372021 Phase 1, Phase 2
29 Treatment of Patients With Optic Neuropathy Using Transorbital Alternating Current Stimulation - a Randomized Trial Completed NCT01270126 Phase 2
30 Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON) Completed NCT01783847 Phase 1, Phase 2 Recombinant human erythropoietin (EPO);Methyl prednisolone
31 Prospective, Unicentric, Randomized, Parallel, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy Recruiting NCT03851562 Phase 2 Alprostadil 20 micrograms;Placebo
32 Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03173638 Phase 2
33 Treatment of Optic Neuropathies Using Autologous Bone-Marrow Derived Clusters of Differentiation (CD) 34+, 133+, and 271+ Stem Cells: A Pilot Study Recruiting NCT02638714 Phase 1, Phase 2
34 Scientific Title: Efficacy of Oral Prednisolone and Erythropoietin Injection in Treatment of Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03715881 Phase 2 Oral prednisolone administration 50 mg;Intravenous Erythropoietin injection
35 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
36 An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene Active, not recruiting NCT02064569 Phase 1, Phase 2
37 A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON) Active, not recruiting NCT02693119 Phase 2 elamipretide (MTP-131) 1% topical ophthalmic solution;Vehicle topical ophthalmic solution
38 Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON) Terminated NCT01389817 Phase 1, Phase 2
39 NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement Completed NCT01411657 Phase 1 NT-501 CNTF Implant
40 A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II) Completed NCT01064505 Phase 1 QPI-1007 at various doses
41 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION) Completed NCT00561834 Phase 1 ranibizumab
42 Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates Completed NCT01404247 Phase 1
43 An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA Recruiting NCT02161380 Phase 1 injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),;injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med);injection of scAAV2-P1ND4v2 2.4 X10e10vg (High);injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
44 Can Urgent Reduction of Intraocular Pressure With Ophthalmic Timolol Improve Recovery From Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): a Randomized Study. Withdrawn NCT01607671 Phase 1 Timolol maleate
45 Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy Unknown status NCT01768260 Aspirin
46 Near to Infrared Light Stimulation Effect on Ganglion Cell Function in Glaucomatous Optic Neuropathy Unknown status NCT00844389 Early Phase 1
47 A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Unknown status NCT01331616 Early Phase 1 Bevacizumab (Avastin)
48 Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) Unknown status NCT00000126
49 A Single Visit, Observational, Follow-up Study of Patients With Leber's Hereditary Optic Neuropathy Following Participation in SNT-II-003 Trial Completed NCT01421381
50 Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy But Without Optic Disc Pit Nor High Myopia Completed NCT01862627

Search NIH Clinical Center for Foster-Kennedy Syndrome

Cochrane evidence based reviews: optic nerve diseases

Genetic Tests for Foster-Kennedy Syndrome

Anatomical Context for Foster-Kennedy Syndrome

MalaCards organs/tissues related to Foster-Kennedy Syndrome:

41
Eye, Bone, Testes, Brain, Endothelial, Retina, Cortex

Publications for Foster-Kennedy Syndrome

Articles related to Foster-Kennedy Syndrome:

(show top 50) (show all 306)
# Title Authors PMID Year
1
Traditional two-dimensional mesenchymal stem cells (MSCs) are better than spheroid MSCs on promoting retinal ganglion cells survival and axon regeneration. 38
31202832 2019
2
Foster Kennedy syndrome. 38
30690544 2019
3
Pheochromocytoma, paragangliomas, and pituitary adenoma: An unusual association in a patient with an SDHD mutation. Case report. 38
31348302 2019
4
Six-month results of suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with optic atrophy: a phase 1/2 study. 38
31309439 2019
5
Foster-Kennedy Syndrome. 38
31227267 2019
6
[Foster Kennedy syndrome secondary to a large meningioma]. 38
31130385 2019
7
A Unique Case of Sinonasal Teratocarcinosarcoma Presenting as Foster Kennedy Syndrome. 38
31084671 2019
8
Chromatic Pupillometry Methods for Assessing Photoreceptor Health in Retinal and Optic Nerve Diseases. 38
30809186 2019
9
Effective Delivery of Exogenous Compounds to the Optic Nerve by Intravitreal Injection of Liposome. 38
30311465 2018
10
Serotype survey of AAV gene delivery via subconjunctival injection in mice. 38
30072815 2018
11
Ganglion cell-inner plexiform layer thickness by swept-source optical coherence tomography in healthy Korean children: Normative data and biometric correlations. 38
30006534 2018
12
Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. 38
29852910 2018
13
[Hereditary Optic Neuropathies]. 38
29490390 2018
14
Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. 38
29552298 2018
15
An overview of the clinical applications of optical coherence tomography angiography. 38
28885606 2018
16
Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy. 38
29853847 2018
17
Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of Retinitis Pigmentosa. 38
30050918 2018
18
Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. 38
30538421 2018
19
The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration. 38
30524222 2018
20
Retinal changes in diabetic patients without diabetic retinopathy. 38
29516043 2017
21
A Promising Tool in Retina Regeneration: Current Perspectives and Challenges When Using Mesenchymal Progenitor Stem Cells in Veterinary and Human Ophthalmological Applications. 38
28643176 2017
22
Mitochondrial dynamics, transport, and quality control: A bottleneck for retinal ganglion cell viability in optic neuropathies. 38
28866056 2017
23
Evidence for Cerebrospinal Fluid Entry Into the Optic Nerve via a Glymphatic Pathway. 38
28973323 2017
24
Unilateral Papilledema in Cerebral Venous Sinus Thrombosis. 38
28936083 2017
25
Optical Coherence Tomography Angiography: A New Tool in Glaucoma Diagnostics and Research. 38
28791067 2017
26
Sequential NAION presenting as pseudo Foster Kennedy syndrome. 38
28431627 2017
27
Intracranial Pressure Influences the Behavior of the Optic Nerve Head. 38
27935009 2017
28
Normative Spectral Domain Optical Coherence Tomography Data in Healthy Turkish Children. 38
26795877 2017
29
Update on the application of optic nerve sheath fenestration. 38
28339414 2017
30
Optic Nerve. 38
27787712 2017
31
Assessment of Rod, Cone, and Intrinsically Photosensitive Retinal Ganglion Cell Contributions to the Canine Chromatic Pupillary Response. 38
28061512 2017
32
[Pay attention on optical coherence tomography evaluation for optic nerve diseases]. 38
27998452 2016
33
Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials. 38
27928464 2016
34
Electrical Stimulation as a Means for Improving Vision. 38
27643530 2016
35
Transcorneal electrical stimulation promotes survival of retinal ganglion cells after optic nerve transection in rats accompanied by reduced microglial activation and TNF-α expression. 38
27569587 2016
36
Visual Cortex Plasticity Following Peripheral Damage To The Visual System: fMRI Evidence. 38
27542799 2016
37
Pseudo-Foster Kennedy Syndrome - a case report. 38
29450361 2016
38
Clinical Usefulness of Spectral-Domain Optical Coherence Tomography in Glaucoma and NAION. 38
27689029 2016
39
Pediatric Optical Coherence Tomography in Clinical Practice-Recent Progress. 38
27409508 2016
40
Pseudo-Foster Kennedy Syndrome as a Rare Presentation of Vitamin B12 Deficiency. 38
27621919 2016
41
Rate of Parental Consanguineous Marriage among Patients with Visual Impairments in Turkey. 38
28293658 2016
42
Bone Marrow-Derived Cells as a Therapeutic Approach to Optic Nerve Diseases. 38
26649049 2016
43
Foster Kennedy Syndrome: An Atypical Presentation. 38
26540474 2015
44
Reduced retinal nerve fibre layer thickness in children with severe obesity. 38
25559237 2015
45
Decreased miR-187 induces retinal ganglion cell apoptosis through upregulating SMAD7 in glaucoma. 38
26463627 2015
46
Pseudo-Foster-Kennedy syndrome with optic nerve compression by the gyrus rectus. 38
26438621 2015
47
Effect of Refractive Status and Axial Length on Peripapillary Retinal Nerve Fibre Layer Thickness: An Analysis Using 3D OCT. 38
26500931 2015
48
Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. 38
26604914 2015
49
The Diagnosis and Treatment of Optic Neuritis. 38
26396053 2015
50
The prevalence and causes of visual impairment in young Turkish men. 38
26430414 2015

Variations for Foster-Kennedy Syndrome

Expression for Foster-Kennedy Syndrome

Search GEO for disease gene expression data for Foster-Kennedy Syndrome.

Pathways for Foster-Kennedy Syndrome

GO Terms for Foster-Kennedy Syndrome

Cellular components related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.46 SDHD SDHC SDHAF2 SDHA
2 mitochondrial inner membrane GO:0005743 9.13 SDHD SDHC SDHA
3 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.8 SDHD SDHC SDHA

Biological processes related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.43 SDHD SDHC SDHA
2 tricarboxylic acid cycle GO:0006099 9.26 SDHD SDHC SDHAF2 SDHA
3 electron transport chain GO:0022900 9.16 SDHC SDHA
4 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.92 SDHD SDHC SDHAF2 SDHA

Molecular functions related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.37 SDHD SDHC
2 electron transfer activity GO:0009055 9.33 SDHD SDHC SDHA
3 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.32 SDHC SDHA
4 ubiquinone binding GO:0048039 8.96 SDHD
5 succinate dehydrogenase activity GO:0000104 8.96 SDHD SDHA
6 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.8 SDHD SDHC SDHA

Sources for Foster-Kennedy Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....